Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SSR3, also known as TRAP-gamma, is a subunit of the signal sequence receptor complex (SSR), which is a component of the translocon-associated protein (TRAP) complex. This endoplasmic reticulum membrane protein plays crucial roles in protein translocation across the ER membrane, integration of nascent polypeptides into the ER, and regulation of signal sequence recognition. It is also involved in transmembrane helix insertion, modulation of ER stress responses, regulation of glycoprotein biosynthesis, and calcium binding. Dysfunction of SSR3 has been implicated in various diseases, including congenital disorders of glycosylation, a severe early-onset progressive encephalopathy syndrome, and certain cancers like hepatocellular carcinoma, suggesting its potential as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Signal sequence receptor subunit 3 (SSR3).